ClinicalTrials.gg
RecruitingNCT07087782Updated May 13, 2026

Impact of Early Fortini Initiation on Growth and Interstage Outcomes in Infants With Single Ventricle Physiology

An interventional study of Fortini formula and Standard Nutritional Care in Single-ventricle, sponsored by Driscoll Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 0 Months to 6 Months. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Driscoll Children's Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
0 Months to 6 Months
Sex
All
01

Study summary

This study is testing whether a special formula called Fortini, which is a high-calorie, low osmolality formula can help high-risk babies with single ventricle physiology grow better after their initial Stage 1 surgical palliation. These babies often struggle to gain weight, which can lead to more health problems before their next surgery.

After their first heart surgery, but prior to discharge, babies will be randomly placed into two groups. One group will get Fortini formula when they leave the hospital, and the other group will get the standard of care high-calorie formula. The primary goal is to see if Fortini helps babies grow better by the time they are ready for their second surgery.

The study will also check if the babies tolerate the formula well, how much they eat, how often they are re-admitted to the hospital, and how their caregivers feel about feeding. The babies will be followed for up to 4 months, until they return for their next surgery. About 100 infants are expected to join the study at Driscoll Children's Hospital.

This research may help improve nutrition care for infants with complex heart conditions and reduce stress for their families.

Read the detailed description

Infants with single ventricle physiology are among the highest-risk pediatric cardiac patients, particularly during the interstage period between Stage 1 and Stage 2 surgical palliation. Suboptimal growth during this time is a well-established predictor of increased morbidity, prolonged hospitalization, and adverse surgical outcomes. Despite advances in interstage monitoring and nutritional support, many infants fail to achieve adequate weight gain, and caregiver burden related to complex feeding regimens remains high.

Current feeding strategies often require fortification to 24-30 kcal/oz using breast milk or standard infant formulas (including hydrolyzed formulas), which may necessitate increased volume or complex mixing that is difficult to sustain at home. Fortini, a commercially available formula providing 30 kcal/oz, is commonly used in older children with failure to thrive or feeding intolerance. It offers the theoretical benefit of providing higher caloric density in a lower volume, which may be advantageous in infants with single ventricle physiology, who often have limited volume tolerance and high metabolic demands.

Preliminary experience and retrospective studies in infants with congenital heart disease suggest that increasing caloric density without increasing volume may support improved weight gain. However, Fortini's use in infants under 6 months-especially those with single ventricle physiology-remains unstudied in a prospective, controlled manner. No data currently exist on its safety, efficacy, or impact on caregiver experience in this vulnerable population. This study seeks to address this gap by examining whether introducing Fortini formula at discharge improves growth and caregiver-reported feeding outcomes in single ventricle infants, compared to current standard nutritional care.

DATA ANALYSIS PLAN:

  1. Descriptive Statistics: Means +/- SD or medians with IQR will summarize demographic and clinical characteristics
  2. Independent t-tests or Mann-Whitney U tests will compare continuous variables (e.g. WAZ change) between groups depending on normality
  3. Chi-square or Fischer's exact tests will compare categorical outcomes (e.g. readmissions, WAZ categories)
  4. Multivariable linear regression will adjust for key confounders such as feeding method (oral vs tube) and WAZ at discharge
  5. Repeated measures ANOVA or linear mixed models may be used if interim weight data points are analyzed longitudinally
  6. Caregiver stress scores will be analyzed with t-tests or Wilcoxon rank-sum tests and categorized for odds ratio as appropriate All statistical tests will use two-sided alpha = -.05 for significance. Analyses will be conducted using SASv9.4 or R.

POWER ANALYSIS:

Based on preliminary data and existing literature:

  1. Expected difference in WAZ change between groups: 0.4 SD
  2. Assumed SD of WAZ change: 0.6
  3. Power: 80%
  4. Alpha: 0.05
  5. Attrition: 15%

To detect a clinically meaningful difference of 0.4 in WAZ:

  1. Required sample size: 34 infants per group (68 total)
  2. Accounting for 15% attrition: 80 infants enrolled Sample size calculations performed using G*Power 3.1

CONFOUNDING VARIABLES:

Key anticipated confounders:

  1. Feeding method (oral vs NG/GT)
  2. Baseline WAZ at discharge
  3. Presence of genetic syndromes
  4. Interstage complications (e.g. infection, hospitalizations)

Plan to address:

  1. Stratified randomization by feeding type and WAZ (\<-2 vs > or equal to -2)
  2. Multivariable regression models to adjust for baseline imbalances

HANDLING MISSING DATA AND OUTLIERS:

  1. Missing outcome data will be assessed for randomness

    • If missing at random (MAR): handled using multiple imputation
    • If not MAR will perform sensitivity analyses to assess impact
  2. Outliers (e.g. extreme WAZ changes or caloric intake values) will be:

    • Verified for data accuracy
    • Retained unless biologically implausible
    • Analyzed with and without to test influence on outcomes (robustness checks)
02

Conditions studied

  • Single-ventricle

Browse trials for

03

In context

Univentricular Heart

86 studies on the registry are indexed under Univentricular Heart; 22 are open to participants now.

This study's planned enrollment of 100 is above the median of 28 across 44 interventional studies indexed under Univentricular Heart.

Browse Univentricular Heart studies →

Lead sponsor

Driscoll Children's Hospital is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infants with single ventricle physiology who have undergone Stage 1 surgical palliation (e.g., Norwood, hybrid, or BT shunt)
  2. Medically stable and ready for discharge from the hospital
  3. Feeding via oral, nasogastric (NG), or gastrostomy tube
  4. Age \< or = 6 months at time of discharge
  5. Parent or legal guardian able to provide

Exclusion criteria

Exclusion Criteria:

  1. Preexisting gastrointestinal condition contraindicating formula use (e.g. NEC, short gut, malabsorption)
  2. to Fortini (e.g. proven cow's milk protein allergy)
  3. Current enrollment in another interventional feeding or nutrition study
  4. Social circumstances likely to preclude safe outpatient follow up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Fortini Formula

    Fortini, a commercially available formula providing 30 kcal/oz

    Other: Fortini formula

  • Active comparator
    Standard nutritional care

    Standard infant formulas (including hydrolyzed formulas) fortification to 24-30 kcal/oz

    Other: Standard Nutritional Care

Interventions

  • OtherFortini formula

    Fortini, a commercially available formula providing 30 kcal/oz, is commonly used in older children with failure to thrive or feeding intolerance. It offers the theoretical benefit of providing higher caloric density in a lower volume, which may be advantageous in infants with single ventricle physiology, who often have limited volume tolerance and high metabolic demands.

  • OtherStandard Nutritional Care

    Standard infant formulas (including hydrolyzed formulas) fortification to 24-30 kcal/oz

06

What researchers measure

Primary outcomes

  1. Change in weight-for-age Z-score (WAZ)

    Change in weight-for-age Z-score (WAZ) from hospital discharge after Stage 1 surgical palliation to Stage 2 surgical evaluation, which is typically 4-6 months after discharge or between 6-9 months of age

    Time frame: 4-6 months

Secondary outcomes

  1. Incidence of feeding intolerance

    Incidence of feeding intolerance (e.g., emesis, diarrhea, constipation requiring change in formula)

    Time frame: 4-6 months

  2. Daily caloric intake

    Average daily caloric intake (kcal/kg/day) during interstage period (4-6 months after hospital discharge)

    Time frame: 4-6 months

  3. Unplanned readmissions

    Number of unplanned readmissions related to feeding or failure to thrive within the 4-6 months after discharge

    Time frame: 4-6 months

  4. Caregiver-reported feeding stress

    Caregiver-reported feeding stress (measured via a validated survey/score on a scale of 1-10 where 1 is no stress and 10 is the most stress)

    Time frame: 4-6 months

  5. Proportion of infants reaching target WAZ

    Proportion of infants reaching target WAZ (\> -1) by Stage 2 or 4-6 months after hospital discharge

    Time frame: 4-6 months

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07087782
Lead sponsor
Driscoll Children's Hospital
Responsible party
Sannya Hede, MD (Prinicpal Investigator, Driscoll Children's Hospital) — Principal investigator
First posted
Jul 28, 2025
Start date
Jul 30, 2025
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
May 13, 2026

Study contacts

Sannya Hede, MD
Contact
sannya.hede@dchstx.org
361-694-5000
Erin Richmond
Contact
erin.richmond@dchstx.org
361-694-5978

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion